Interventions for HIV and hepatitis C virus infections in recreational drug users

Clinical Infectious Diseases

Volumn 50, Issue 11, 2010, Pages 1505-1511

  Khalsa, Jag H ^a   Elkashef, Ahmed ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; METHADONE; PEGINTERFERON; RECREATIONAL DRUG; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL CONSUMPTION; BEHAVIOR THERAPY; BONE MARROW SUPPRESSION; DEPRESSION; DRUG ABUSE; DRUG INDUCED HEADACHE; FATIGUE; FEVER; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE MODIFICATION; MIXED INFECTION; MYALGIA; PANCYTOPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY; SUICIDAL IDEATION; SUICIDE;

HEPATITIS C; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; SUBSTANCE-RELATED DISORDERS;

EID: 77951867442     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652447     Document Type: Review

References (87)

1. United Nations Office on Drugs and Crime. World drug report 2009. Report E.09.XI.12. Vienna, Austria: United Nations, 2009.
2. Substance Abuse and Mental Health Services Administration (SMA). Results from the 2008 National Survey on Drug Use and Health: national findings. HHS publication SMA-09-4134. Rockville, MD: Office of Applied Studies, Department of Health and Human Services, 2009.
3. World Health Organization. Hepatitis C. Geneva, Switzerland: World Health Organization, 2003.
4. United Nations AIDS (UNAIDS). 2009 AIDS epidemic update. Report UNAIDS/09-36E/JC1700E. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS/WHO, 2009.
5. Centers for Disease Control and Prevention. HIV infection among injection drug users-34 states, 2004-2007. MMWR Morb Mortal Wkly Rep 2009;58:1291-1316.
6. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-529.
7. Sullivan LE, Fiellin DA. Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am J Addict 2004; 13:1-20. (Pubitemid 38294860)
8. Hammer GP, Kellogg TA, McFarland WC, et al. Low incidence and prevalence of hepatitis C virus infection among sexually active nonintravenous drug-using adults, San Francisco, 1997-2000. Sex Transm Dis 2003;30:919-924.
9. Hagan H, Des J. HIV and HCV infection among injecting drug users. Mt Sinai J Med 2000;67:423-428.
10. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C (HCV) infection and HCV-related chronic diseases. MMWR Morb Mortal Wkly Rep 1998;47:1-39.
11. Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis 2001;28:166-170.
12. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
13. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183:1466-11175 (Pubitemid 32417698)
14. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1 December 2009. http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentGL .pdf. Accessed 20 January 2010.
15. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185. (Pubitemid 36618128)
16. Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 2009;66: 715-726.
17. Baxter JD, Mayers DL, Wentworth DN, et al; for the CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-F93.
18. Palella FJ Jr, Delaney KM, Moorman AC, et al; for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
19. Detels R, Munoz A, McFarlane G, et al; for the Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-1503.
20. Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 1994;36:109-113. (Pubitemid 24297670)
21. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin. J Epidemiol Community Health 1996; 50:534-537. (Pubitemid 26387989)
22. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-oftreatment: an 18-month prospective follow-up. J Acquir Immune Defie Syndr 1993;6:1049-1056. (Pubitemid 23239778)
23. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994;8:223-231.
24. Soriano V, Ramos B, Nunez M, et al. Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype. J Infect Dis 2005; 192:1245-1248. (Pubitemid 41368425)
25. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997;336:1097-1100.
26. O'Connor PG. HIV post-exposure therapy for drug users in treatment. J Subst Abuse Treat 2000; 18:17-21.
27. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injectiondrug users with human immunodeficiency virus infection. N Engl J Med 1994;331:450-459.
28. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med 1992;93:382-386.
29. Khalsa J, Genser S, Vocci F, Francis H, Bean P. The challenging interactions between antiretroviral agents and addiction drugs. Am Clin Lb 2002;21:10-13.
30. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006;43(suppl 4):S235-S246.
31. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006; 43(suppl 4):S224-S234.
32. McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006; 15:23-34.
33. Hershow RC, Kalish LA, Sha B, Till M, Cohen M. Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Sex Transm Dis 1998; 25:527-532.
34. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230-238.
35. Karim B, Alex G, Smith AL, Hardikar W. Hepatitis C infection in children: a Melbourne perspective. J Paediatr Child Health 2000;36:385-388.
36. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008; 6:69-75.
37. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
38. Keating S, Coughlan S, Connell J, Sweeney B, Keenan E. Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area. Ir J Med Sci 2005;174:37-41.
39. Lucidarme D, Bruandet A, lief D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the north and east of France. Epidemiol Infect 2004; 132:699-708.
40. Garcia F, Roldan C, Garcia F Jr, et al. Subtype distribution among intravenous drug users with chronic type C hepatitis in southern Spain. Microbios 1998;95:15-24.
41. Cilla G, Garcia-Bengoechea M, Perez-Trallero E, Montalvo I, Vicente D, Arenas JI. Genotyping of hepatitis C virus isolates from Basque Country, Spain. Epidemiol Infect 1996;117:533-536.
42. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
43. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002;117(suppl 1):S126-S134.
44. Curtis CL, Mills EJ. Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduct J 2006; 3:31.
45. Litwin AH, Harris KA Jr, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37:32-110
46. Dieperink E, Willenbring M, Ho SB. Neuropsychiatrie symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876.
47. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003;9:93-110.
48. Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev 2008; 1:177-187.
49. Hauser P. Neuropsychiatrie side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 2004;33(suppl 1):S35-S50.
50. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
51. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retroviral 1998;18(suppl 1):S11-S19.
52. Quaglio G, Lugoboni F, Pajusco B, et al. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis 2003;37:33-40. (Pubitemid 36836642)
53. MacDonald MA, Wodak AD, Dolan KA, van BI, Cunningham PH, Kaldor JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997: collaboration of Australian NSPs. Med J Aust 2000; 172:57-61.
54. Law MG. Modelling the hepatitis C virus epidemic in Australia: Hepatitis C Virus Projections Working Group. J Gastroenterol Hepatol 1999; 14:1100-1107.
55. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171-184. (Pubitemid 36206602)
56. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005;25:18-32. (Pubitemid 40322348)
57. Falusi OM, Pulvirenti J, Sarazine J, Shastri P, Gail C, Glowacki R. HIVinfected inpatients in the HAART era: how do hepatitis C virus coinfected patients differ? AIDS Patient Care STDS 2003; 17:13-16.
58. Voirin N, Trepo C, Miailhes P, et al. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database. J Viral Hepat 2004; 11:559-562. (Pubitemid 39486620)
59. Piccolo P, Borg L, Lin A, Melia D, Ho A, Kreek MJ. Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. J Addict Dis 2002; 21: 55-66. (Pubitemid 35204995)
60. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 2005; 19(suppl 3):S13-S19. (Pubitemid 41682164)
61. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatrie impact of hepatitis C on advanced HIV. Neurology 2004; 62:957-962.
62. Grassi L, Satriano J, Serra A, et al. Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human im- munodeficiency virus infections in intravenous drug users. Psychother Psychosom 2002;71:342-349.
63. May T, Lewden C, Bonnet F, et al. Causes and characteristics of death among HIV-I infected patients with immunovirologic response to antiretroviral treatment [in French], Presse Med 2004;33:1487-1492.
64. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005;42:799-805.
65. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18:757-770.
66. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-1199.
67. Serfaty L, Costagliola D, Wendum D, et al. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a casecontrol study. AIDS 2001;15:2011-2016.
68. Di Martino V, Thevenot T, Boyer N, et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 2002; 16:441-445.
69. Carlos MJ, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004;5:125-131.
70. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
71. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-1923.
72. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
73. National Institutes of Health. Management of hepatitis C: NIH consensus statement. Bethesda, MD: National Institutes of Health, 2009.
74. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C. Hepatology 2002; 36:S3-S20.
75. Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C: 2002. Hepatology 2002; 36(5 suppl 1):S1-S2.
76. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
77. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40(suppl 5):S276-S285.
78. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005;40(suppl 5):S321-S324.
79. Kresina TF, Khalsa J, Cesari H. Francis H. Hepatitis C virus infection and substance abuse: medical management and developing models of integrated care: an introduction. Clin Infect Dis 2005;40(suppl 5):S259-S262.
80. Hu DJ, Subbarao S, Vanichseni S, et al. Frequency of HIV-1 dual subtype infections, including intcrsubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 2005;19(3):303-308.
81. Cacoub P, Goderel I, Morlat P, et al. Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. Epidemiol Infect 2005; 133:305-314.
82. Taylor LE, Gholam PM, Schwartzapfel B, Rich JD. Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report. AIDS Read 2005; 15:629-638.
83. Lozano Polo JL, Gutierrez ME, Martinez PV, Santamaria GJ, Vada SJ, Vallejo Correas JA. Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection [in Spanish], Rev Clin Esp 1997;197:479-483.
84. Huber M, Weber R, Oppliger R, et al. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005; 33: 25-29.
85. Strauss SM, Astone JM, Hagan H, Des J. The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. J Urban Health 2004;81:38-47.
86. Astone J, Strauss SM, Vassilev ZP, Des J. Provision of hepatitis C education in a nationwide sample of drug treatment programs. J Drug Educ 2003;33:107-117. (Pubitemid 36583240)
87. Walley AY, White MC, Kushel MB, Song YS, Tulsky JP. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005;28:181-187. (Pubitemid 40380926)